RT Journal Article
SR Electronic
T1 Supervised exercise training in patients with cancer during anthracycline-based chemotherapy to mitigate cardiotoxicity – a randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.06.23285559
DO 10.1101/2023.02.06.23285559
A1 Schneider, Caroline
A1 Ryffel, Christoph
A1 Rabaglio, Manuela
A1 Suter, Thomas M.
A1 Campbell, Kristin L.
A1 Eser, Prisca
A1 Wilhelm, Matthias
YR 2023
UL http://medrxiv.org/content/early/2023/02/08/2023.02.06.23285559.abstract
AB Background Exercise training (ET) has been shown to mitigate cardiotoxicity of anthracycline-based chemotherapies (AC) in animal models. Data from randomized controlled trials in patients with cancer are sparse.Methods Patients with breast cancer or lymphoma receiving AC were recruited from four cancer centres and randomly assigned to three months supervised ET during (EXduringAC) or after (EXpostAC) AC. All patients were counselled on physical activity (PA) and PA was objectively measured with an activity tracker with PA feedback option. Primary endpoint was change in left ventricular global longitudinal strain (GLS) between baseline and AC completion (AC-end) assessed by transthoracic 2D echocardiography. Secondary endpoints were change in high sensitivity Troponin T (hsTnT) and NT-pro-brain natriuretic peptide (NT-proBNP) between baseline and AC-end. Exploratory analyses were performed at 6 months (follow-up). Primary and exploratory analysis were performed by linear mixed models and robust linear models, respectively.Results One-hundred-and-forty-three patients were eligible for the study. Fifty-seven patients (median age 47 [1st and 3rd quartiles 38, 57] years; 95% women) consented to participate, of whom 28 and 29 patients were randomized to the EXduringAC and EXpostAC group, respectively. GLS deteriorated in both study groups from baseline to AC-end with 7.4% and 6.2% relative increase in EXduringAC and EXpostAC, respectively, and hsTnT and NT-proBNP significantly increased in both groups, without difference between groups for any parameter. Duration of moderate-to-vigorous PA (MVPA) was also similar between groups with a median of 33 [26, 47] min/day and 32 [21, 59] min/day in the EXduringAC and EXpostAC group, respectively. In the robust linear model including the pooled patient population, MVPA was significantly associated with a more negative GLS and lesser increase in hsTnT.Conclusion In physically active patients with cancer receiving AC, supervised ET during chemotherapy was not superior to PA advice and tracker monitoring only to mitigate cardiotoxicity. Objectively measured PA was inversely related to markers of LV function and myocardial injury.What is new?This is the first study to demonstrate a significant inverse association between objectively measured MVPA and markers of LV dysfunction and myocardial injury.Objectively measured PA revealed that in physically active patients with cancer, the addition of supervised ET did not result in more PA compared to PA advice and feedback by activity trackers alone.What are the clinical implications?In a physically active cohort, PA counselling combined with PA tracking represents a viable alternative compared to supervised ET to mitigate cardiotoxicity and should be offered to patients undergoing AC.Our findings suggest that there is a dose-response relationship between PA and cardioprotective effects during AC.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trials.gov: NCT03850171Funding StatementThe study was funded by a Swiss Cancer Research Grant to the CAPRICE study under grant number HSR-4360-11-2017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Local Ethic Committee of the Canton of Bern, SwitzerlandI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data underlying this article will be shared upon reasonable request to the corresponding author.ACanthracycline-based chemotherapiesBPBlood pressureCVCardiovascularCVDCardiovascular DiseaseCRFCardiorespiratory fitnessCORECardio-oncologic rehabilitation programmeCPETCardiopulmonary exercise testEFEjection fractionETexercise trainingGLSGlobal longitudinal strainhs-CRPhigh-sensitivity C-Reactive ProteinhsTNThigh-sensitive Troponin-TLAVIleft atrial end-systolic volume indexLVLeft ventricularLVEDVLeft ventricular end-diastolic volumeLVEDViLeft ventricular end-diastolic volume indexLVESVLeft ventricular end-systolic volumeMVPAModerate to vigorous physical activityNT-proBNPN-terminal pro-brain natriuretic peptidePAPhysical activityQOLQuality of life